Bill Gates Reveals $500M+ Healthcare Investment Strategy at J.P. Morgan 2018 Conference

“No matter where I go or with whom I discuss, there is one point I want everyone to be aware of. That is"Based on over a decade of observation, I have concluded that the healthcare industry is developing, and at an accelerating pace."——Bill· Gates. 

Today, healthcare has become Bill Gates’ most favored investment sector. In 2017, Bill Gates personally and the Bill & Melinda Gates Foundation made a total of 22 investments, 14 of which were in the healthcare sector, accounting for 64% of all investment activities, with a total investment amount exceeding $500 million.

At the J.P. Morgan Healthcare Conference on January 9, 2018, Gates once again revealed the operational model of his foundation.

Since retiring from Microsoft, he has been focusing onBill· Bill & Melinda Gates Foundation(hereinafter referred to as the Gates Foundation)Work, now nearly9 years.During this period, the foundation successivelyDonated $12 billion to the global healthcare sector.

Most of these funds have been donated to projects that benefit children in Africa. Africa is the region with the fastest-growing child population, where many parents lack control and choice over the number of children they will have in the future. In contexts characterized by underdeveloped medical resources and rampant infectious diseases, local child mortality rates remain extremely high.

After Gates set the goal of reducing child mortality, related vaccines and cost-effective medical devices became investment targets.

Meanwhile, innovative therapies and R&D are also key investment focuses, particularly cross-disciplinary R&D.“Since it has been confirmed that the HIV virus can eliminate tumors, could we conversely explore how tumors might be leveraged to treat HIV?” Gates remarked at the conference, using this analogy.

Addressing the imbalance in medical resources and exploring treatment options for diseases that currently lack cures are key focus areas of the Bill & Melinda Gates Foundation.How Is the Massive Capital Allocated, and How Does Bill Gates Put His Investment Logic into Practice? VCBeat (WeChat ID: vcbeat) Has Compiled a Detailed Overview of the Bill & Melinda Gates Foundation’s 2017 Healthcare Investments.

In 2006, Warren Buffett donated the majority of his wealth to the Bill & Melinda Gates Foundation, likening this gesture to his most successful investment. Vaccines constitute the most significant component of this investment.

As early as 2016, the Bill & Melinda Gates Foundation provided $38 million to Takeda Pharmaceutical Company of Japan to develop a low-cost oral inactivated polio vaccine. In 2017, the Gates Foundation made two investments in the vaccine sector.

In February 2017, the Bill & Melinda Gates Foundation invested $6 million in Vaxess Technologies, a biotechnology company based in Massachusetts. Founded in 2010, Vaxess Technologies is developing a silk fibroin-based polymer platform for the encapsulation and stabilization of biological compounds. The company is working to commercialize the use of silk fibroin to stabilize vaccines, enabling their storage without refrigeration.

Because vaccines are temperature-sensitive, they may lose efficacy due to excessive heat at any stage from the manufacturing department to the site of administration. To ensure that vaccines used in planned immunization programs are properly refrigerated throughout the entire process—including production, storage, transportation, distribution, and administration—they must be kept continuously under specified cold-chain conditions, thereby safeguarding their appropriate potency.

Cold chain transportation largely preserves vaccine efficacy, but it is also costly. The supporting infrastructure for the cold chain includes low-temperature cold storage units for vaccine storage, ice-pack quick freezers, conventional cold storage facilities, dedicated refrigerated vehicles for vaccine transport, vaccine transport trucks, refrigerators, cold boxes, insulated backpacks, as well as computers and spare parts. Apart from the costs incurred during transportation, the equipment itself and its routine maintenance entail substantial expenditures. Ultimately, these costs are factored into the price of vaccines.

If Vaxess Technologies’ technology can be commercialized, the cold-chain transportation of vaccines may become a thing of the past, and its impact will be disruptive. At the same time, the cost of vaccines will also drop significantly.

In addition, Vaxess Technologies is also researching a novel sustained-release microneedle to transform the method of vaccine administration.

The second company is called PnuVax, into which the Bill & Melinda Gates Foundation invested $29.4 million in October 2017. This Canadian vaccine manufacturing company boasts 30 years of experience in vaccine production.

PnuVax has disclosed that it will allocate the funds obtained to the clinical evaluation of its innovative pneumococcal vaccine. Although many pneumococcal vaccines are currently commercialized, there remains a significant gap in this therapeutic area. Each year, a large number of children under five years of age die from pneumonia infections. Furthermore, such vaccines are prohibitively expensive and suffer from supply shortages, making it difficult for developing countries to benefit from them.

PnuVax possesses proprietary patented technology and has developed novel vaccines capable of covering multiple serotypes and various strains of Streptococcus pneumoniae; combined with the company’s manufacturing platform, this approach is expected to significantly reduce the cost of such vaccines.

Price Guarantee and Quality GuaranteeThis is the Gates Foundation’s primary consideration in the vaccine sector. Low-income countries are the regions with the greatest need for vaccines, yet market mechanisms fail to ensure access for children from impoverished families. These households cannot afford the costs, and local governments are unable to cover healthcare expenses for such large populations. While philanthropy offers an entry point, its capacity is limited; encouraging the market to develop low-cost vaccines represents a more sustainable long-term strategy.

Furthermore, Gates partnered with corporations and governments to establish Gavi, the Vaccine Alliance. The alliance is responsible for connecting R&D companies and government resources with developing countries. Since 2000, it has helped vaccinate 580 million children worldwide.

In a 2017 open letter to Warren Buffett, Bill and Melinda Gates noted that coverage of basic childhood vaccines had reached an all-time high of 86%, with the gap between the wealthiest and poorest countries narrowing to its lowest level in history. While vaccination is critical to reducing child mortality, this coverage rate still falls short of reaching all children worldwide.

“Governments and businesses must redouble their efforts; we need to reduce the number of child deaths to below 3 million by 2030,” Bill and Melinda Gates wrote in an open letter.

Gates’ focus on the vaccine sector is largely aimed at benefiting impoverished regions by reducing child mortality through vaccination.

However, vaccines are by no means the only approach. As early as March 2015, the Bill & Melinda Gates Foundation donated $75.99 million to a disease surveillance network in developing countries. This surveillance network aims to leverage mobile phone data to rapidly identify the causes and locations of childhood illness and death, while also dedicating efforts to the prevention and control of epidemic diseases such as Ebola.

Improving the balance of medical resources in developing countries through new technologies is also an approach favored by Bill Gates and his foundation.

In November 2017, the Bill & Melinda Gates Foundation provided a $100,000 grant to a laboratory at Johns Hopkins University for research on infant care monitoring devices. Researchers at the laboratory aim to develop a neonatal monitoring system on mobile phones to help mothers of newborns in remote areas promptly detect whether their infants are suffering from serious illnesses.

Students from the university witnessed the harsh medical conditions faced by rural residents while traveling in regions such as Bangladesh, Kenya, and Uganda. Approximately 2.7 million newborns die annually in these areas, with 75% of these deaths occurring within the first week after birth. Due to limited healthcare resources and a lack of medical knowledge among local residents, family members often struggle to promptly identify signs of illness in newborns during the early stages.

Upon learning of the situation, the researchers decided to provide assistance to the infant’s mother. To this end, they designed a simple health assessment system consisting of a mobile phone equipped with a test attachment and accompanying testing software. The attachment is a low-cost paper-based sensor that can be strapped to the infant’s abdomen. The mother simply needs to select “Yes” or “No” in response to prompts provided by the software.

It is understood that this funding will help researchers develop low-cost sensors and accompanying mobile apps. If progress goes smoothly, the project will receive an additional $1 million in funding.

Not only that, but the Gates Foundation also provided a $9.6 million grant to the Institute for Healthcare Improvement in September 2017 to reduce maternal and neonatal mortality in Ethiopia.

In November 2017, the Bill & Melinda Gates Foundation also held discussions with the Federal Ministry of Health regarding collaboration with the Pakistani government, including innovative technology projects in areas such as polio eradication and maternal and child health. It is reported that the initiative has received strong administrative support, but it will still need to undergo further government review.

In a public letter, the Gateses wrote that, in addition to saving children’s lives, they hoped to help young couples in remote areas gain the ability to choose how many children to have.

“If parents believe their children can survive and they can space their pregnancies, they have the ability to choose how many children to have,” Melinda Gates wrote in her letter.

“When a mother can choose the number of children she has, those children are more likely to be healthy, and parents will have more time and financial resources to invest in each child’s health and education. This is how families and nations can escape poverty,” added Bill Gates.

Vaccines can help reduce neonatal mortality to some extent, but a fundamental solution requires preventive measures starting before birth.

In his speech that day, Gates also mentioned that the foundation is currently funding a 20-year study on the association between epidemic outbreaks in sub-Saharan Africa and stillbirths, which may also bring benefits to developed countries.

As an increasing number of people in impoverished countries enter the middle class, they may consume more beef and milk; however, excessive meat consumption could lead to higher incidence rates of obesity and heart disease.。

In affluent countries, advocating for a balanced dietary structure is feasible; however, this is not necessarily the case in low-income nations. Furthermore, it remains challenging for households in impoverished regions to secure the necessary nutritional intake.

After addressing survival concerns, “living healthily” became the next focus. In August 2017, Bill Gates invested in two “cultured meat” companies at once.

Impossible Foods is a plant-based burger company founded in 2011.

After years of effort, Impossible Foods’ plant-based burger has finally become a reality. This burger boasts the aroma and texture of real beef burgers, but its patty is made using plant-derived heme instead of animal-derived heme. Like genuine beef, this “artificial meat” changes color during cooking and releases a savory, meaty fragrance.

It is reported that Impossible Foods’ plant-based burgers are already on sale at restaurants in New York, with each burger priced as high as $12 (approximately RMB 80).

Bill Gates personally participated in the company’s new round of financing in August 2017, which was led by Singapore’s Temasek Holdings.

Another company is Memphis Meats. Founded in 2015 and based in California, USA, Memphis Meats is developing a novel method of meat production: cultivating meat directly from animal cells, thereby eliminating the need to feed, breed, and slaughter actual animals.

Compared with conventional animal farming, this production method can reduce greenhouse gas emissions by up to 90%, while also decreasing the consumption of water and land resources.

The company completed a $17 million Series A financing round in August 2017, with participation from the Bill & Melinda Gates Foundation and 13 other investment institutions.

In addition, the Gates Foundation funded a plant research institute—the Donald Danforth Plant Science Center—in January 2017. Established in 1998 as a non-profit organization, it aims to combat hunger, improve human health, and protect the environment through plant science research.

The Gates Foundation provided the institution with a $61 million grant in January 2017. Additionally, the U.S. Department of Energy provided it with $160 million in funding in October.

Artificial intelligence rose rapidly in 2017 and is poised for swift implementation in the healthcare sector, with the Bill & Melinda Gates Foundation also making initial forays into this field.

In November 2017, the Gates Foundation invested in MACRO-EYES, a machine learning company. This healthcare services enterprise launched its artificial intelligence solution, Sibyl, in September 2017 to help patients schedule their appointments efficiently.

Patients’ scheduling needs are often overlooked, which can in fact lead to significant problems. Sibyl is a scheduling system that can be integrated into hospitals’ existing systems, leveraging AI to analyze patients’ appointment histories and healthcare-related data characteristics. It also incorporates factors such as providers and locations, each patient’s time constraints, and preferences.

This system enables hospitals to better serve patients.

This solution’s capabilities come into play before patients arrive at a healthcare system. The system can inform patients of specific details, such as the type of care and the provider’s name, helping both parties schedule an optimal appointment time.

The current price of this system is $25,000 per year.

Of course, biomedicine is the top priority, after all, there are still many diseases for which no effective therapeutic drugs have been found.

In 2017, the Bill & Melinda Gates Foundation invested in a total of six biopharmaceutical-related companies, accounting for 57% of its annual investment portfolio. These investments specifically covered monoclonal antibodies, recombinant lactoferrin-based therapeutics, and immunotherapies, spanning areas such as epidemic diseases, infectious diseases, oncology, and HIV/AIDS treatment.

Particularly in the field of infectious diseases, Gates revealed that the company has raised a $500 million venture capital fund for investments in infectious disease prevention and control.

In January 2017, the Bill & Melinda Gates Foundation participated in a new round of financing for Vir Biotechnology. This technology-driven biopharmaceutical company is dedicated to integrating novel technologies into the treatment and patient care of serious infectious diseases. Vir Biotechnology is developing innovative therapeutic solutions, including prophylactic and immunotherapeutic approaches, through its diversified programs and platforms.

Vir Biotechnology's research areas mainly include the following three directions:

1. Chronic infectious diseases, including chronic communicable diseases such as hepatitis B, tuberculosis, and HIV/AIDS;

2. Respiratory diseases, including influenza virus, respiratory syncytial virus (RSV), and human metapneumovirus (MPV);

3. Acquired viral infections.

The company was co-founded by Robert Nelsen, founder of the top venture capital firm ARCH Venture Partners, and Klaus Frueh, a senior scientist at Oregon Health & Science University. ARCH Venture Partners participated in the company’s seed financing round.

The Bill & Melinda Gates Foundation has invested $150 million in Vir Biotechnology. Previously, Vir Biotechnology had received investments from world-renowned institutions such as Altitude Life Sciences, Alta Partners, Baillie Gifford, the Alaska Permanent Fund, SoftBank, and Temasek.

Another company that received investment is Kymab, a monoclonal antibody developer. Founded in 2009, this UK-based biotechnology firm received a $9 million investment from the Bill & Melinda Gates Foundation on January 10, 2017.

Kymab’s core technology is its proprietary Kymouse platform, through which the company aims to develop high-quality fully human monoclonal antibody therapeutics. Researchers can use this platform to capture B lymphocytes from the human immune system and generate fully human antibody drugs targeting known or novel clinical targets.

Monoclonal antibody drugs have demonstrated advantages in treating inflammatory and immune-mediated diseases, such as rheumatoid arthritis and psoriasis. Kymab is developing next-generation bispecific antibodies primarily targeting inflammatory diseases.

One of Kymab’s projects is OX40, a drug that can drive T cells to treat inflammatory diseases. The project officially entered clinical trials in 2017.

In October 2016, the company also entered into a mutual licensing and collaborative development agreement with China-based Acmab Biopharma. Under this agreement, both parties will leverage Acmab Biopharma’s proprietary FIT-Ig bispecific antibody technology and Kymab’s proprietary Kymouse fully human monoclonal antibody technology to develop novel bispecific antibodies targeting tumor immunology.

Another monoclonal antibody company is Arsanis, which received two rounds of investment from the Bill & Melinda Gates Foundation in February and April 2017, respectively. The first round amounted to $9.3 million; the second round involved seven institutional investors with a total investment of $455 million.

Arsanis’s antibody-based therapeutics primarily target pathogenic infections, with its lead candidate, ASN100, having advanced to Phase II clinical trials. Currently indicated for the treatment of Staphylococcus aureus infections, ASN100 delivers targeted action against the pathogen during therapy. This approach may enable Arsanis to achieve therapeutic efficacy without disrupting the patient’s gut microbiota or contributing to antibiotic resistance.

It is reported that the company was listed on NASDAQ in October 2017.

In the same month, the Gates Foundation also invested in a monoclonal antibody company called Visterra, which was founded in 2007.

Visterra primarily focuses on the development of novel therapeutics for the prevention and treatment of serious diseases. Its proprietary Hierotope platform enables the identification of disease-specific targets, thereby facilitating the development of precise antibody-based therapies by researchers.

The company’s lead candidate, VIS410, is a broad-spectrum monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza, primarily indicated for the treatment of influenza A (H1N1).

In the Phase 2a clinical trial, researchers conducted a controlled study comparing VIS410 with placebo. Within 24 hours, participants were randomly administered either VIS410 or placebo. The final results demonstrated that patients treated with VIS410 had significantly lower viral loads in nasal secretions compared to the control group.

Visterra is currently conducting a Phase 2a clinical trial of VIS410 for influenza A (H1N1) worldwide, with a Phase 2b trial expected to take place in 2018. Another candidate drug, VIS513, targeting dengue fever, is also anticipated to enter Phase 1 clinical trials in the same year.

Also securing financing in the same month was Ventria Bioscience, a well-established biopharmaceutical company founded in 1993. In 2012, the company acquired the French firm Meristem Therapeutics, thereby obtaining all intellectual property rights related to Meristem Therapeutics’ recombinant lactoferrin.

However, Meristem Therapeutics’ patents are unable to resolve the challenges associated with the industrial-scale production of protein therapeutics, whereas Ventria Bioscience’s proprietary pipeline patent, ExpressTec, can increase protein yields by 25-fold.

The company’s lead candidate, VEN100, is a recombinant human lactoferrin therapeutic primarily indicated for the prevention of antibiotic-associated diarrhea (AAD) in adults. Currently, VEN100 is undergoing clinical development, while the company is also exploring various clinical indications for recombinant human lactoferrin and other pipeline products.

With the rise of immunotherapy companies such as Novartis, Kite, and JUNO, immunotherapy garnered significant attention in 2017. On September 18, 2017, the Bill & Melinda Gates Foundation invested in Immunocore, a UK-based immunotherapy company.

Immunocore, founded in 2008, is a UK-based biotechnology company focused on the development of novel T-cell receptor therapeutics, primarily targeting cancer and viral diseases. Although Immunocore is considerably more low-profile than star players such as Kite and JUNO, its CD3 manufacturing process is indeed world-leading.

Immunocore’s core technology is called ImmTAC, a platform that shares similarities with bispecific antibody platforms. Classic bispecific antibodies contain two single-chain variable fragments (scFv), with one end binding to CD3 on T cells and the other end binding to the antigen CD19 on cancer cells. In this way, the antibody molecule acts as a bridge between cancer cells and T cells, delivering efficacy many times greater than that of traditional monoclonal antibodies. ImmTAC replaces the scFv that binds to the antigen with a T-cell receptor (TCR), which also binds to specific antigens.

In 2016, Immunocore stated in a paper that their ImmTAV molecules could recognize the HIV Gag antigen at one end and bind to CD3 to recruit CD8+ T cells at the other, thereby enabling the targeted clearance of 85% of virus-infected cells. This finding attracted significant attention within the industry.

Immunocore’s first candidate drug, imcgp100, has entered clinical trials, primarily targeting patients with metastatic melanoma. The superiority of ImmTAV holds promise for extending the reach of immunotherapy to HIV/AIDS.

In addition to these, new drugs for the diagnosis and treatment of chronic diseases such as Alzheimer's disease are also worthy of attention.

Rising living standards and advances in modern medicine have significantly increased human life expectancy in recent decades. While this is a welcome development, the risk of conditions such as arthritis and Parkinson’s disease also rises with age.

In the United States, Alzheimer’s disease is one of the top ten causes of death and the only one among them without an effective treatment—annual incidence rateare all increasing.

As the U.S. baby boom generation enters old age, this trend will continue to expand. “This means that more families will watch helplessly as their loved ones’ cognitive abilities decline and then slowly fade away,” Gates wrote in an article.

Despite the growing disease burden, scientists have yet to determine what causes Alzheimer’s disease or how to prevent it from damaging the brain.

Compared to older adults without neurodegenerative diseases, patients with Alzheimer’s disease or other forms of dementia spend five times more annually on out-of-pocket medical expenses. Unlike many individuals with chronic conditions, Alzheimer’s patients must cover both the costs of long-term care and direct medical expenditures. If diagnosed in one’s sixties or seventies, one may require expensive care for the subsequent decades.

These expenditures represent one of the fastest-growing healthcare burdens in developed countries. According to data provided by the Alzheimer’s Association, Americans will spend $259 billion in 2017 on care for patients with Alzheimer’s disease and other dementias. Gates worries that, absent major breakthroughs, these costs will continue to strain fiscal budgets in the coming years or even decades.

In November 2017, Gates personally invested $50 million in the Dementia Discovery Fund, a private equity fund dedicated to expanding the pipeline of novel clinical drugs and identifying new therapeutic targets. Additionally, Gates disclosed that he would also make a personal $50 million investment in a startup company developing Alzheimer’s disease medications.

The above outlines the investment layout of Bill Gates personally and his foundation in the healthcare sector in 2017. It is evident that their key areas of focus include major diseases yet to be conquered, chronic diseases, and medical aid in underdeveloped regions. Similarly, these areas represent typical healthcare demands.

In economically developed countries, the advancement of modern medicine has extended life expectancy, but it has also led to a year-on-year increase in the incidence of chronic diseases, thereby generating a demand for chronic disease management. On the other hand, technological progress has enabled a more accurate understanding of diseases, making cures possible for conditions such as cancer and liver disease. Consequently, market demand for medical treatments targeting these diseases has reached unprecedented levels.

Conversely, in impoverished regions with scarce medical resources, although there is demand for treatment of major critical illnesses, the need for infectious disease prevention and control as well as cost-effective products is more urgent due to various factors such as economic constraints and limited transportation access.

Gates also highlighted several specific goals in healthcare, such as consigning tuberculosis to history and declaring war on Alzheimer’s disease. It is believed that in the coming years, chronic diseases, major malignancies, and the prevention and control of birth defects in impoverished regions will remain areas of his sustained focus.